Horizon Discovery licenses cancer cell-lines to top US Cancer Pharma Genentech
Horizon has signed a commercial agreement to supply top US Cancer Pharma Genentech with two cell-lines targeted against specific cancer genes. The specific terms of the deal remain confidential but involve the payment of up-front, annual renewal and milestone payments.
Two further deals are in negotiation and are expected to complete over the next twelve months.